| Description |
Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)[1].
|
| Related Catalog |
|
| Target |
BAFF-R[1]
|
| In Vitro |
Ianalumab (0.1 μg/mL; 72 h) 对慢性淋巴细胞白血病 (CLL) 自然杀伤细胞的强抗体依赖性细胞毒性 (ADCC)，促进细胞因子的产生[1]。
|
| In Vivo |
Ianalumab (总剂量: 100 mg/kg; 每周一次, 持续 2 周) 增加 CLL 小鼠模型的小鼠存活率[1]。 Ianalumab (10 mg/kg; 每周一次, 持续 6 周) 经 Ibrutinib (HY-10997) 调节 NK 细胞的 ITAM 后，表现出功能增强[1]。 Animal Model: Em-TCL1 adoptive transplant model of murine CLL[1] Dosage: 10 mg/kg Administration: Injection; once weekly for 6 weeks Result: Ibrutinib enhanced VAY-736 activity through an ITAM function on NK cells.
|
| References |
[1]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460.
|
